We are live on !
Find out more
WWB
Windward Bio Group
About: Windward Bio Group AG is a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. Its flagship program is WIN378, a potentially novel, long-acting, anti-TSLP monoclonal antibody. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bi-specific, which has therapeutic application across immunological diseases.
News
Positive
Neutral
Negative
Sentiment
3-Months
Positive
0%
Neutral
0%
Negative
0%
We haven’t received any recent news articles for WWB
Price charts implemented using Lightweight Charts™